Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation
Authors:
- 1 November 1996
- journal article
- case report
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 94 (5) , 358-364
Abstract
Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Our institution averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41; 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse while matter changes. EEG - both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potentials - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remained on MRI. As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.Keywords
This publication has 18 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy after cardiac transplantationNeurology, 1988
- CYCLOSPORIN-ASSOCIATED CEREBRAL LESIONS IN LIVER TRANSPLANTATIONThe Lancet, 1988
- Cyclosporine-Associated Central Nervous System ToxicityNew England Journal of Medicine, 1988
- Cerebral blindness and encephalopathy with cyclosporin A toxicityNeurology, 1987
- Convulsions associated with cyclosporin A in transplant recipients.BMJ, 1985
- CYCLOSPORINE-ASSOCIATED CENTRAL NERVOUS SYSTEM TOXICITY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1984
- Complex Visual Hallucinations and CyclosporineArchives of Neurology, 1984
- Nephrotoxicity of Cyclosporin a after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1981
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979